Related Experiment Video
Updated: Jan 27, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables
Shivani Srivastava1, Alexander I Salter1, Denny Liggitt2
1Program in Immunology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3-100, Seattle, WA 98109-1024, USA.
Abstract:
Many potential targets for CAR-T cells in solid tumors are expressed in some normal tissues, raising concern for off-tumor toxicity. Following lymphodepletion, CAR-T cells targeting the tumor-associated antigen ROR1 lysed tumors in mice but induced lethal bone marrow failure due to recognition of ROR1+ stromal cells. To improve selectivity, we engineered T cells with synthetic Notch (synNotch) receptors specific for EpCAM or B7-H3, which are expressed on ROR1+ tumor cells but not ROR1+ stromal cells. SynNotch receptors induced ROR1 CAR expression selectively within the tumor, resulting in tumor regression without toxicity when tumor cells were segregated from, but not when co-localized with, normal ROR1+ cells. This strategy, thus, permits safe targeting of tumors that are sufficiently separated from normal cells.
Insights
Engineered T-cells with synthetic Notch (synNotch) receptors target ROR1+ tumor cells selectively. This approach enables CAR-T cell therapy for solid tumors by preventing off-tumor toxicity in normal tissues.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- CAR-T cell therapy faces challenges in solid tumors due to off-tumor toxicity.
- Targeting tumor-associated antigens like ROR1 can lead to severe adverse effects in normal tissues.
Purpose of the Study:
- To develop a more selective CAR-T cell strategy for solid tumors.
- To engineer T-cells that can distinguish between tumor and normal cells expressing ROR1.
Main Methods:
- Utilized synthetic Notch (synNotch) receptors for conditional CAR expression.
- Designed synNotch receptors targeting EpCAM or B7-H3 on ROR1+ tumor cells.
- Evaluated CAR-T cell efficacy and toxicity in mouse models.
Main Results:
- SynNotch receptors enabled ROR1 CAR expression exclusively in tumor cells.
- Achieved significant tumor regression without inducing bone marrow failure.
- Demonstrated safety when tumor cells were spatially separated from normal ROR1+ cells.
Conclusions:
- SynNotch receptor technology enhances CAR-T cell selectivity for solid tumors.
- This strategy mitigates off-tumor toxicity by targeting tumor-specific antigens.
- Safe and effective CAR-T cell therapy is feasible for solid tumors with appropriate targeting strategies.
Related Concept Videos
Receptor-mediated Endocytosis
Receptor-mediated Endocytosis
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Internal Receptors
Cell Specific Gene Expression

